Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion type Assertion NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_head.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion description "[De novo or augmented inhaled glucocorticoid therapy was associated with significant reductions in the percentages of CD4 T cells expressing IL-5 and IL-4 mRNA, as well as improvements in lung function, symptom scores, and bronchial hyperresponsiveness to metacholine (PD20) in both the atopic and nonatopic asthmatics.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_provenance.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion evidence source_evidence_literature NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_provenance.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion SIO_000772 11826234 NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_provenance.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion wasDerivedFrom befree-2016 NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_provenance.
- NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_assertion wasGeneratedBy ECO_0000203 NP343994.RAWWNHMWTES97gaX-W4-yGQ1QQD-ui18WeXoFxX2cEjJY130_provenance.